@prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix nt: . @prefix xsd: . @prefix orcid: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { schema:possibleTreatment sub:medtherapy . sub:medtherapy prov:wasDerivedFrom sub:quote; schema:drug ; schema:targetPopulation sub:targetpop; nkg:indicationType nkg:AdjunctiveTherapy . sub:quote prov:value "Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures."; prov:wasQuotedFrom . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "UTEeHwYfV6inHkcTx2niWTf7Ohg0EvKibWcmaNMj3Ihdt6p0yT4KiP1ugQM8N7TQQjuPVFGUpRv9fQOyBuq4cQK+AFZYnqJI21Klqou6PhLmHl9MnO4AbKImtxWzY85mKAUSBk1fu/Stn3+g8MzsxUK+trpMUv65C19FOkK6OQo="; npx:hasSignatureTarget this: . this: dct:created "2021-04-03T11:32:11.095+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }